Heavy metals modulate the activity of the purinergic P2X4 receptor.
To further characterize the nature of the regulatory metal-binding sites of the rat P2X(4) receptor, several transition heavy metals were tested to examine their ability to mimic the facilitator action of zinc or the inhibitory action of copper. cDNA coding for the rat P2X(4) receptor was injected into Xenopus laevis oocytes; the two-electrode voltage-clamp technique was used to measure and quantify the ATP-evoked currents in the absence or presence of the metals. Cadmium facilitated the ATP-gated currents in a reversible and voltage-independent manner; maximal potentiation occurred within less than 1 min. Cadmium displaced leftward, in a concentration-dependent manner, the ATP concentration-response curve. In contrast, mercury reduced the ATP-gated currents in a reversible, time, and concentration manner. Maximal inhibition occurred after about 5 min of metal application. Cobalt also augmented the ATP-evoked currents, but its action was long lasting and did not reverse even after 45 min of metal washout. Other metals such as lead, nickel, manganese, silver, or gallium did not significantly alter the ATP-gated currents. The co-application of cadmium plus zinc or mercury plus copper caused additive effects. Mutation of H140 by alanine (H140A) augmented both the cadmium-induced facilitation and the mercury-induced inhibition. In contrast, the H241A mutant showed characteristics indistinguishable from the wild type. The H286A mutant showed a normal cadmium-induced potentiation, but an increased mercury inhibition. Out of the metals examined, only cadmium mimicked closely the action of zinc, evidencing commonalities. While mercury mimicked the action of copper, both metals apparently interact at distinct metal-binding sites. The present findings allow us to infer that heavy metals modulate the P2X(4) receptor by acting in at least three separate metal-binding sites.
Coddou
Claudio
C
Centro Regulación Celular y Patología Prof. J.V. Luco, Instituto Milenio de Biología Fundamental y Aplicada, MIFAB, Departamento de Fisiología, P. Universidad Católica de Chile, Casilla 114-D, Santiago 1, Chile.
Lorca
Ramón A
RA
Acuña-Castillo
Claudio
C
Grauso
Marta
M
Rassendren
Francois
F
Huidobro-Toro
J Pablo
JP
D000255:Adenosine Triphosphate / Q000096:biosynthesis / Q000494:pharmacology; D000818:Animals; D001665:Binding Sites / Q000187:drug effects / Q000235:genetics; D003545:Cysteine / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D005071:Evoked Potentials / Q000187:drug effects / Q000502:physiology; D045604:Extracellular Fluid / Q000737:chemistry; D006639:Histidine / Q000737:chemistry / Q000494:pharmacology; D019216:Metals, Heavy / Q000037:antagonists & inhibitors / Q000494:pharmacology; D009154:Mutation; D009865:Oocytes / Q000187:drug effects / Q000502:physiology; D058919:Purinergic P2 Receptor Antagonists; D018048:Receptors, Purinergic P2 / Q000187:drug effects* / Q000235:genetics; D058848:Receptors, Purinergic P2X4; D018675:Toxicity Tests / Q000379:methods; D014982:Xenopus laevis
D019216:Metals, Heavy; C548228:P2rx4 protein, rat; D058919:Purinergic P2 Receptor Antagonists; D018048:Receptors, Purinergic P2; D058848:Receptors, Purinergic P2X4; D006639:Histidine; D000255:Adenosine Triphosphate; D003545:Cysteine